FR12C0077I2 - Composition pour le traitement des condylomes génitaux - Google Patents

Composition pour le traitement des condylomes génitaux

Info

Publication number
FR12C0077I2
FR12C0077I2 FR12C0077C FR12C0077C FR12C0077I2 FR 12C0077 I2 FR12C0077 I2 FR 12C0077I2 FR 12C0077 C FR12C0077 C FR 12C0077C FR 12C0077 C FR12C0077 C FR 12C0077C FR 12C0077 I2 FR12C0077 I2 FR 12C0077I2
Authority
FR
France
Prior art keywords
treatment
composition
genital warts
warts
genital
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0077C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Inst Chinese Academy Medical Sciences
Mitsui Norin Co Ltd
Original Assignee
Cancer Inst Chinese Academy Medical Sciences
Mitsui Norin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Inst Chinese Academy Medical Sciences, Mitsui Norin Co Ltd filed Critical Cancer Inst Chinese Academy Medical Sciences
Publication of FR12C0077I1 publication Critical patent/FR12C0077I1/fr
Application granted granted Critical
Publication of FR12C0077I2 publication Critical patent/FR12C0077I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
FR12C0077C 1996-11-18 2012-12-20 Composition pour le traitement des condylomes génitaux Active FR12C0077I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP32119596A JP3213557B2 (ja) 1996-11-18 1996-11-18 茶カテキンを有効成分として含有する尖圭コンジローマ治療剤

Publications (2)

Publication Number Publication Date
FR12C0077I1 FR12C0077I1 (fr) 2013-02-01
FR12C0077I2 true FR12C0077I2 (fr) 2013-08-16

Family

ID=18129859

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0077C Active FR12C0077I2 (fr) 1996-11-18 2012-12-20 Composition pour le traitement des condylomes génitaux

Country Status (13)

Country Link
US (1) US5795911A (fr)
EP (1) EP0842660B1 (fr)
JP (1) JP3213557B2 (fr)
KR (1) KR100312252B1 (fr)
CN (1) CN1086290C (fr)
AT (1) ATE288266T1 (fr)
AU (1) AU716120B2 (fr)
CA (1) CA2221370C (fr)
DE (2) DE69732402T2 (fr)
ES (1) ES2232849T3 (fr)
FR (1) FR12C0077I2 (fr)
PT (1) PT842660E (fr)
TW (1) TW371628B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968973A (en) * 1996-11-18 1999-10-19 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method for treating hyperplasia
US6197808B1 (en) * 1996-11-18 2001-03-06 Cancer Instititute (Hospital), Chinese Academy Of Medical Sciences Methods for treating hyperplasia
CN1063957C (zh) 1997-09-29 2001-04-04 北京华颐中药制药厂 一种金荞麦制剂的制备方法
JP2003525839A (ja) 1997-09-29 2003-09-02 ベイジン・ファイ・チャイニーズ・ファーマスーティカル・ファクトリー 金蕎麦群成物、その製造方法および分析方法並びにその使用
EP0938897A1 (fr) * 1997-12-26 1999-09-01 Japanese Foundation For Cancer Research Inhibiteur de la telomerase
US6030622A (en) * 1998-06-23 2000-02-29 Shehadeh; Ahmad Abdallah Herbal extract composition and method with immune-boosting capability
CA2338328A1 (fr) * 1998-07-21 2000-02-03 Thomas Jefferson University Petites molecules inhibitrices de proteines bcl-2
KR100319973B1 (ko) * 1998-12-05 2002-04-22 이인수 녹차카테킨을 유효성분으로 하는 자궁경부 상피내종양 예방 또는 치료제 조성물
DE60236273D1 (de) 2001-05-03 2010-06-17 Cornell Res Foundation Inc Behandlung von krankheiten, die durch hpv verursacht werden
DE10156794B4 (de) 2001-11-19 2006-05-18 Medigene Ag Arzneimittel zur Behandlung von Warzen
PT1448186E (pt) * 2001-11-19 2009-03-24 Medigene Ag Medicamento para o tratamento de doenças virais da pele e doenças tumorais
US7972632B2 (en) 2003-02-28 2011-07-05 Unigen Pharmaceuticals, Inc. Identification of Free-B-Ring flavonoids as potent COX-2 inhibitors
US7108868B2 (en) 2002-03-22 2006-09-19 Unigen Pharmaceuticals, Inc. Isolation of a dual cox-2 and 5-lipoxygenase inhibitor from acacia
US8945518B2 (en) * 2002-04-30 2015-02-03 Unigen, Inc. Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions
DE60328676D1 (de) * 2002-04-30 2009-09-17 Unigen Pharmaceuticals Inc Formulierung eines gemisches aus flavonoiden und flavanen mit freiem b ring als therapeutisches mittel
US8034387B2 (en) * 2002-04-30 2011-10-11 Unigen, Inc. Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments
US7780992B2 (en) 2002-12-08 2010-08-24 Tareq Abduljalil Albahri Antiviral medicament
AU2004228021B2 (en) * 2003-04-04 2010-09-02 Unigen, Inc. Formulation of dual cycloxygenase (COX) and lipoxygenase (LOX) inhibitors for mammal skin care
US7763588B2 (en) * 2003-06-13 2010-07-27 The Salk Institute For Biological Studies Method for increasing cognitive function and neurogenesis
EP1660109A4 (fr) * 2003-09-02 2009-04-08 Unigen Pharmaceuticals Inc Formulation d'un melange de flavonoides et de flavanes a cycle b utilise dans la prevention et le traitement du declin cognitif et des anomalies de la memoire dues a l'age
US20050079235A1 (en) * 2003-10-09 2005-04-14 Eggert Stockfleth Use of a polyphenol for the treatment of actinic keratosis
AU2004281525B2 (en) 2003-10-09 2010-01-28 Aresus Pharma GmbH The use of a polyphenol for the treatment of a cancerous or pre-cancerous lesion of the skin
CN100337690C (zh) * 2005-02-07 2007-09-19 上海复旦张江生物医药股份有限公司 一种评价治疗尖锐湿疣药物有效性的方法
US20070082073A1 (en) * 2005-05-18 2007-04-12 University Of South Florida Catechin Adjuvants
US8044098B2 (en) * 2005-08-02 2011-10-25 Shenghua Guangzhou Pharmaceutical Science & Technology Co., Ltd. Use of hydroxybenzoic acids and their esters and analogues for preventing or treating virus infection
KR100801891B1 (ko) 2006-11-02 2008-02-12 한상진 천연물질을 이용한 생식기 염증 예방 또는 치료용 약제학적 조성물
EP2179722A1 (fr) 2008-10-24 2010-04-28 Heinrich-Pette-Institut für experimentelle Virologie und Immunologie Formation topique pour la prévention de la transmission sexuelle d'une infection virale
ES2349966B1 (es) * 2008-10-30 2011-11-18 Ignacio Umbert Millet Formulaciones topicas para el tratamiento de verrugas.
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
WO2012100835A1 (fr) 2011-01-28 2012-08-02 Laboratorios Del Dr. Esteve, S.A. Méthodes et compositions pour le traitement du sida
WO2014110284A1 (fr) 2013-01-09 2014-07-17 Bacterin International, Inc. Substitut de greffe osseuse contenant un agent de contraste temporaire et un procédé de génération et un procédé d'utilisation associés
JP2018512450A (ja) 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
MX367243B (es) * 2016-02-04 2019-08-09 Maria Del Carmen Ramirez Olvera COMPOSICIÓN DE EXTRACTOS DE PLANTAS QUE INCREMENTAN LOS BACILOS DE DöDERLEIN, USADA PARA EL TRATAMIENTO DE ENFERMEDADES DE TRANSMISIÓN SEXUAL (ETS) Y DEL VIRUS DEL PAPILOMA HUMANO (VPH), CON EFECTO AFRODISIACO.
CN106727275A (zh) * 2016-12-15 2017-05-31 珠海聚焦先导生物研究院有限公司 一种治疗阴道炎的栓剂组合物
CN107349197A (zh) * 2017-07-13 2017-11-17 黄冈师范学院 一种儿茶素在制备治疗皮肤乳头状瘤的药物上的应用
WO2024003061A1 (fr) 2022-06-30 2024-01-04 Lo.Li. Pharma S.R.L. Composition pour le traitement de l'infection par le papillomavirus humain (vph)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2128207B1 (fr) * 1971-03-11 1974-08-02 Zyma Sa
US5159069A (en) * 1988-12-20 1992-10-27 Yamanouchi Pharmaceutical Co., Ltd. Sulfated tannins and their salts
JP2727471B2 (ja) * 1989-09-14 1998-03-11 三井農林株式会社 インフルエンザウィルス感染予防剤
JPH03141220A (ja) * 1989-10-26 1991-06-17 Tsumura & Co 抗レトロウイルス剤
JP3019996B2 (ja) * 1990-03-01 2000-03-15 三井農林株式会社 白癬治療剤
US5211944A (en) * 1990-10-12 1993-05-18 Shaman Pharmaceuticals, Inc. Proanthocyanidin polymers having antiviral activity and methods of obtaining same
DE4211238C2 (de) * 1992-04-03 1994-10-27 Edward I Budowskij Verwendung von 2',5'-Oligoadenylaten zur Behandlung von Papillomatosen
US5605929A (en) * 1992-05-27 1997-02-25 Arch Development Corp. Methods and compositions for inhibiting 5α-reductase activity
US5648377A (en) * 1993-12-21 1997-07-15 Indena S.P.A. Formulations containing carotenoids an procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
GB2293548A (en) * 1994-09-29 1996-04-03 Joan Louise Hibberd Treatment of herpes infections
IT1275905B1 (it) * 1995-03-14 1997-10-24 Indena Spa Frazioni polifenoliche di te', loro uso e formulazioni che le contengono
US5576013A (en) * 1995-03-21 1996-11-19 Eastern Virginia Medical School Treating vascular and neoplastic tissues
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法

Also Published As

Publication number Publication date
CA2221370A1 (fr) 1998-05-18
JPH10147525A (ja) 1998-06-02
DE69732402T2 (de) 2006-01-19
DE69732402D1 (de) 2005-03-10
AU4443897A (en) 1998-06-04
CN1185947A (zh) 1998-07-01
FR12C0077I1 (fr) 2013-02-01
TW371628B (en) 1999-10-11
JP3213557B2 (ja) 2001-10-02
AU716120B2 (en) 2000-02-17
DE122009000072I1 (de) 2010-03-25
EP0842660B1 (fr) 2005-02-02
DE122009000072I2 (de) 2011-07-21
ES2232849T3 (es) 2005-06-01
PT842660E (pt) 2005-05-31
CA2221370C (fr) 2004-03-02
US5795911A (en) 1998-08-18
KR100312252B1 (ko) 2002-02-19
KR19980042555A (ko) 1998-08-17
CN1086290C (zh) 2002-06-19
EP0842660A1 (fr) 1998-05-20
ATE288266T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
MA25823A1 (fr) Compositions pour le traitement de l'eau.
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE60019158D1 (de) Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
DE69519577D1 (de) Prednisolonmetasulfobenzoatzusammensetzung zur behandlung von entzündungserkrankung des darmes
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
FR2786390B1 (fr) Cotyle de correction pour emploi dans le traitement de pathologies de la hanche
DE69622461T2 (de) Oberflächenbehandlungszusammensetzung
FR2758465B1 (fr) Composition pour le traitement de l'amiante
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
MA23837A1 (fr) Benzamides pour le traitement de degenerescenses neurologiques
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
FR2694384B1 (fr) Traitement de la surface de réfractaires.
FR2786096B1 (fr) Composition pour la prevention et le traitement topique de la cellulite
FR2751544B1 (fr) Composition therapeutique pour le traitement des verrues vulgaires
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
FR2721930B1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
DZ3320A1 (fr) Complexe comprenant de l'eletriptane et de la sulphobutylether-cyclodextrine pour le traitement de la migraine
FR2751637B1 (fr) Cellule d'electrocoagulation pour le traitement d'effluents
FR2759290B1 (fr) Minalcipran pour le traitement de l'incontinence urinaire